Lumipulse® G ADxPLORER® NPTX2
Immunoassay to be used with the automated LUMIPULSE® G1200 system for the quantitative measurement of neuronal pentraxin-2 (NPTX2) in human serum, plasma and cerebrospinal fluid (CSF).
This product is for research use only (RUO), not for use in diagnostic procedures.
Product # 70101
Product # 70102
Product # 70103
Click here to navigate
- Contact sales for information
- Details
- Conditions of sale
- Insights
- Product inquiry
- Related products
- Webinars
-
Details
Synaptic dysfunction is an early-stage indicator of pathology progression and neurodegeneration and appears to correlate to the degree of cognitive decline. NPTX2 could potentially be a relevant synaptic biomarker for observing disease evolution or treatment response in patients with neurodegenerative diseases such as dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), Parkinson's disease (PD) and psychiatric disorders such as schizophrenia1,2, but its clinical value still needs to be further explored. In addition, it may represent an important therapeutic target for TDP-43 proteinopathies3.
The assay was developed utilizing an ADx proprietary NPTX2 monoclonal antibody ADx410 (Code#ADx410) in conjunction with an alkaline phosphatase-conjugated Fab fragment derived from ADx recombinant mAb ADx409 (Code#ADx409). The assay is calibrated with recombinant NPTX2 full length protein.
References:
- Das et al. Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer's disease and frontotemporal dementia. Alzheimers Res Ther. 2023 Mar 24;15(1):62.
- Göverti et al. Neuronal pentraxin-2 (NPTX2) serum levels during an acute psychotic episode in patients with schizophrenia. Psychopharmacology (Berl). 2022 Aug;239(8):2585-2591.
- Hruska-Plochan et al. A model of human neural networks reveals NPTX2 pathology in ALS and FTLD. Nature. 2024 Feb;626(8001):1073-1083.
-
Conditions of sale
Please contact your local Fujirebio representative to obtain the end user conditions of sale for this product.
-
Insights
Mar 31, 2026Integration of ADx NeuroSciences Within Fujirebio Unleashes a World of New Possibilities
Fujirebio Europe N.V. will formally and fully integrate ADx NeuroSciences N.V. into its organization on April 1, 2026. This completes a process that...
Mar 31, 2026CAP Today Article - Alzheimer's blood tests poised to lead
For a pathology that is invariably associated with dimming—of memory, of relationships, of personality—
Alzheimer’s disease has been linked to...
Nov 19, 2025When To Use Blood-Based Biomarkers For Alzheimer's Disease Assessment
Accelerating Alzheimer’s diagnosis with blood-based biomarker testing
Studies indicate that patients may wait an average of more than three years for...
-
Product inquiry
-
Related products